Does the media favor ACAD or ADMA?

In the previous week, ADMA Biologics had 18 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 51 mentions for ADMA Biologics and 33 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.80 beat ADMA Biologics' score of 0.05 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 11 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ADMA Biologics 5 Very Positive mention(s) 3 Positive mention(s) 38 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ADMA or ALLO?

In the previous week, ADMA Biologics had 49 more articles in the media than Allogene Therapeutics. MarketBeat recorded 51 mentions for ADMA Biologics and 2 mentions for Allogene Therapeutics. ADMA Biologics' average media sentiment score of 0.05 beat Allogene Therapeutics' score of 0.00 indicating that ADMA Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 5 Very Positive mention(s) 3 Positive mention(s) 38 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Allogene Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, PCVX or ADMA?

ADMA Biologics has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vaxcyte N/A N/A -$766.63M -$7.63 N/A ADMA Biologics $510.17M 4.51 $146.93M $0.70 14.19

Is PCVX or ADMA more profitable?

ADMA Biologics has a net margin of 32.98% compared to Vaxcyte's net margin of 0.00%. ADMA Biologics' return on equity of 40.17% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets Vaxcyte N/A -37.56% -33.62% ADMA Biologics 32.98% 40.17% 26.97%

Does the media refer more to PCVX or ADMA?

In the previous week, ADMA Biologics had 31 more articles in the media than Vaxcyte. MarketBeat recorded 51 mentions for ADMA Biologics and 20 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.68 beat ADMA Biologics' score of 0.05 indicating that Vaxcyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 10 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ADMA Biologics 5 Very Positive mention(s) 3 Positive mention(s) 38 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, IBRX or ADMA?

ADMA Biologics has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmunityBio $113.29M 70.12 -$351.40M -$0.97 N/A ADMA Biologics $510.17M 4.51 $146.93M $0.70 14.19

Does the media prefer IBRX or ADMA?

In the previous week, ADMA Biologics had 33 more articles in the media than ImmunityBio. MarketBeat recorded 51 mentions for ADMA Biologics and 18 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 0.35 beat ADMA Biologics' score of 0.05 indicating that ImmunityBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 4 Very Positive mention(s) 5 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral ADMA Biologics 5 Very Positive mention(s) 3 Positive mention(s) 38 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor RYTM or ADMA?

In the previous week, ADMA Biologics had 26 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 51 mentions for ADMA Biologics and 25 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.47 beat ADMA Biologics' score of 0.05 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral ADMA Biologics 5 Very Positive mention(s) 3 Positive mention(s) 38 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

ADMA Biologics (ADMA) Competitors

$9.94 +0.04 (+0.35%)

As of 10:49 AM Eastern

Compare

ADMA vs. ACAD, ALLO, PCVX, IBRX, and RYTM

Should you buy ADMA Biologics stock or one of its competitors? MarketBeat compares ADMA Biologics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ADMA Biologics include ACADIA Pharmaceuticals (ACAD), Allogene Therapeutics (ALLO), Vaxcyte (PCVX), ImmunityBio (IBRX), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "biotechnology" industry.

How does ADMA Biologics compare to ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and ADMA Biologics (NASDAQ:ADMA) are both mid-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.

ACADIA Pharmaceuticals has higher revenue and earnings than ADMA Biologics. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	4.75	$391M	$2.22	13.30
ADMA Biologics	$510.17M	4.51	$146.93M	$0.70	14.19

ACADIA Pharmaceuticals has a net margin of 33.42% compared to ADMA Biologics' net margin of 32.98%. ADMA Biologics' return on equity of 40.17% beat ACADIA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%
ADMA Biologics	32.98%	40.17%	26.97%

96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are held by insiders. Comparatively, 3.9% of ADMA Biologics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

ACADIA Pharmaceuticals currently has a consensus target price of $33.44, suggesting a potential upside of 13.24%. ADMA Biologics has a consensus target price of $18.67, suggesting a potential upside of 87.89%. Given ADMA Biologics' higher probable upside, analysts clearly believe ADMA Biologics is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.82
ADMA Biologics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, ADMA Biologics had 18 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 51 mentions for ADMA Biologics and 33 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.80 beat ADMA Biologics' score of 0.05 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	11 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADMA Biologics	5 Very Positive mention(s)	3 Positive mention(s)	38 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

ACADIA Pharmaceuticals has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market.

Summary

ACADIA Pharmaceuticals beats ADMA Biologics on 11 of the 16 factors compared between the two stocks.

How does ADMA Biologics compare to Allogene Therapeutics?

ADMA Biologics (NASDAQ:ADMA) and Allogene Therapeutics (NASDAQ:ALLO) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

ADMA Biologics has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$510.17M	4.51	$146.93M	$0.70	14.19
Allogene Therapeutics	$20K	35,567.71	-$190.89M	-$0.77	N/A

In the previous week, ADMA Biologics had 49 more articles in the media than Allogene Therapeutics. MarketBeat recorded 51 mentions for ADMA Biologics and 2 mentions for Allogene Therapeutics. ADMA Biologics' average media sentiment score of 0.05 beat Allogene Therapeutics' score of 0.00 indicating that ADMA Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	5 Very Positive mention(s)	3 Positive mention(s)	38 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Allogene Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ADMA Biologics has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.48, suggesting that its share price is 52% less volatile than the broader market.

ADMA Biologics currently has a consensus target price of $18.67, suggesting a potential upside of 87.89%. Allogene Therapeutics has a consensus target price of $8.52, suggesting a potential upside of 313.50%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Allogene Therapeutics is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 3.9% of ADMA Biologics shares are held by insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

ADMA Biologics has a net margin of 32.98% compared to Allogene Therapeutics' net margin of 0.00%. ADMA Biologics' return on equity of 40.17% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.98%	40.17%	26.97%
Allogene Therapeutics	N/A	-56.45%	-40.36%

Summary

ADMA Biologics beats Allogene Therapeutics on 10 of the 17 factors compared between the two stocks.

How does ADMA Biologics compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and ADMA Biologics (NASDAQ:ADMA) are both mid-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.

Vaxcyte presently has a consensus target price of $86.00, suggesting a potential upside of 46.24%. ADMA Biologics has a consensus target price of $18.67, suggesting a potential upside of 87.89%. Given ADMA Biologics' higher possible upside, analysts clearly believe ADMA Biologics is more favorable than Vaxcyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38
ADMA Biologics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 3.3% of Vaxcyte shares are held by insiders. Comparatively, 3.9% of ADMA Biologics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Vaxcyte has a beta of 1.23, indicating that its stock price is 23% more volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market.

ADMA Biologics has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A
ADMA Biologics	$510.17M	4.51	$146.93M	$0.70	14.19

ADMA Biologics has a net margin of 32.98% compared to Vaxcyte's net margin of 0.00%. ADMA Biologics' return on equity of 40.17% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-37.56%	-33.62%
ADMA Biologics	32.98%	40.17%	26.97%

In the previous week, ADMA Biologics had 31 more articles in the media than Vaxcyte. MarketBeat recorded 51 mentions for ADMA Biologics and 20 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.68 beat ADMA Biologics' score of 0.05 indicating that Vaxcyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	10 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADMA Biologics	5 Very Positive mention(s)	3 Positive mention(s)	38 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ADMA Biologics beats Vaxcyte on 10 of the 15 factors compared between the two stocks.

How does ADMA Biologics compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and ADMA Biologics (NASDAQ:ADMA) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

ADMA Biologics has a net margin of 32.98% compared to ImmunityBio's net margin of -598.55%. ADMA Biologics' return on equity of 40.17% beat ImmunityBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-598.55%	N/A	-51.65%
ADMA Biologics	32.98%	40.17%	26.97%

8.6% of ImmunityBio shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 66.1% of ImmunityBio shares are owned by company insiders. Comparatively, 3.9% of ADMA Biologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

ImmunityBio currently has a consensus price target of $14.20, indicating a potential upside of 89.46%. ADMA Biologics has a consensus price target of $18.67, indicating a potential upside of 87.89%. Given ImmunityBio's stronger consensus rating and higher probable upside, equities research analysts clearly believe ImmunityBio is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
ADMA Biologics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, ADMA Biologics had 33 more articles in the media than ImmunityBio. MarketBeat recorded 51 mentions for ADMA Biologics and 18 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 0.35 beat ADMA Biologics' score of 0.05 indicating that ImmunityBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	4 Very Positive mention(s)	5 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
ADMA Biologics	5 Very Positive mention(s)	3 Positive mention(s)	38 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

ImmunityBio has a beta of 0.03, meaning that its stock price is 97% less volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market.

ADMA Biologics has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	70.12	-$351.40M	-$0.97	N/A
ADMA Biologics	$510.17M	4.51	$146.93M	$0.70	14.19

Summary

ADMA Biologics beats ImmunityBio on 10 of the 16 factors compared between the two stocks.

How does ADMA Biologics compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and ADMA Biologics (NASDAQ:ADMA) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

Rhythm Pharmaceuticals has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market.

ADMA Biologics has higher revenue and earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	41.91	-$196.54M	-$3.11	N/A
ADMA Biologics	$510.17M	4.51	$146.93M	$0.70	14.19

75.7% of ADMA Biologics shares are owned by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are owned by company insiders. Comparatively, 3.9% of ADMA Biologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

ADMA Biologics has a net margin of 32.98% compared to Rhythm Pharmaceuticals' net margin of -85.59%. ADMA Biologics' return on equity of 40.17% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%
ADMA Biologics	32.98%	40.17%	26.97%

Rhythm Pharmaceuticals currently has a consensus target price of $142.44, indicating a potential upside of 22.73%. ADMA Biologics has a consensus target price of $18.67, indicating a potential upside of 87.89%. Given ADMA Biologics' higher probable upside, analysts plainly believe ADMA Biologics is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78
ADMA Biologics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, ADMA Biologics had 26 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 51 mentions for ADMA Biologics and 25 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.47 beat ADMA Biologics' score of 0.05 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	6 Very Positive mention(s)	1 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
ADMA Biologics	5 Very Positive mention(s)	3 Positive mention(s)	38 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ADMA Biologics beats Rhythm Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get ADMA Biologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADMA vs. The Competition

Export

Metric	ADMA Biologics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.30B	$3.71B	$7.02B	$12.96B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	14.21	9.07	269.90	24.97
Price / Sales	4.51	1,294.66	659.13	107.89
Price / Cash	15.14	44.95	28.89	37.44
Price / Book	4.94	17.71	11.29	6.44
Net Income	$146.93M	-$13.25M	$3.45B	$347.50M
7 Day Performance	13.67%	5.42%	3.56%	3.82%
1 Month Performance	9.42%	-1.71%	-0.57%	-0.37%
1 Year Performance	-39.86%	61.70%	77.67%	23.81%

ADMA Biologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADMA ADMA Biologics	4.3336 of 5 stars	$9.94 +0.4%	$18.67 +87.9%	-40.1%	$2.30B	$510.17M	14.21	530	Earnings Report Gap Up
ACAD ACADIA Pharmaceuticals	4.3226 of 5 stars	$25.61 -1.0%	$32.31 +26.1%	+18.7%	$4.43B	$1.07B	11.64	510	Earnings Report Analyst Upgrade Insider Trade Analyst Revision
ALLO Allogene Therapeutics	1.8662 of 5 stars	$1.84 -2.1%	$8.52 +363.2%	+93.3%	$648.89M	$20K	N/A	310	Upcoming Earnings
PCVX Vaxcyte	2.7451 of 5 stars	$53.53 -1.0%	$86.00 +60.7%	+94.2%	$7.81B	N/A	N/A	160	Earnings Report Analyst Upgrade
IBRX ImmunityBio	2.3847 of 5 stars	$7.15 -0.3%	$14.20 +98.6%	+213.1%	$7.51B	$113.29M	N/A	590	Positive News Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADMA) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ADMA Biologics (ADMA) Competitors

ADMA vs. ACAD, ALLO, PCVX, IBRX, and RYTM

How does ADMA Biologics compare to ACADIA Pharmaceuticals?

Summary

How does ADMA Biologics compare to Allogene Therapeutics?

Summary

How does ADMA Biologics compare to Vaxcyte?

Summary

How does ADMA Biologics compare to ImmunityBio?

Summary

How does ADMA Biologics compare to Rhythm Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADMA vs. The Competition

ADMA Biologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ADMA Biologics (ADMA) Competitors

ADMA vs. ACAD, ALLO, PCVX, IBRX, and RYTM

How does ADMA Biologics compare to ACADIA Pharmaceuticals?

Which has preferable earnings & valuation, ACAD or ADMA?

Is ACAD or ADMA more profitable?

Do institutionals and insiders hold more shares of ACAD or ADMA?

Do analysts rate ACAD or ADMA?

Does the media favor ACAD or ADMA?

Which has more risk and volatility, ACAD or ADMA?

Summary

How does ADMA Biologics compare to Allogene Therapeutics?

Which has better earnings and valuation, ADMA or ALLO?

Does the media refer more to ADMA or ALLO?

Which has more volatility & risk, ADMA or ALLO?

Do analysts rate ADMA or ALLO?

Do insiders & institutionals hold more shares of ADMA or ALLO?

Is ADMA or ALLO more profitable?

Summary

How does ADMA Biologics compare to Vaxcyte?

Do analysts prefer PCVX or ADMA?

Do institutionals & insiders hold more shares of PCVX or ADMA?

Which has more risk and volatility, PCVX or ADMA?

Which has preferable earnings and valuation, PCVX or ADMA?

Is PCVX or ADMA more profitable?

Does the media refer more to PCVX or ADMA?

Summary

How does ADMA Biologics compare to ImmunityBio?

Is IBRX or ADMA more profitable?

Do institutionals and insiders believe in IBRX or ADMA?

Do analysts recommend IBRX or ADMA?

Does the media prefer IBRX or ADMA?

Which has more volatility & risk, IBRX or ADMA?

Which has stronger valuation & earnings, IBRX or ADMA?

Summary

How does ADMA Biologics compare to Rhythm Pharmaceuticals?

Which has more volatility & risk, RYTM or ADMA?

Which has preferable earnings & valuation, RYTM or ADMA?

Do insiders and institutionals believe in RYTM or ADMA?

Is RYTM or ADMA more profitable?

Do analysts recommend RYTM or ADMA?

Does the media favor RYTM or ADMA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADMA vs. The Competition

ADMA Biologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools